• OncoSil gets Ethics committee approval
  • Starpharma’s  nasal spray VIRALEZE granted approval in Malaysia
  • Botanix Pharmaceuticals strikes deal in Korea


Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committee approved its investigator initiated clinical trial.

The PANCOSIL trial, to be led by renowned surgeon Professor Marc Besselink of Amsterdam UMC, is now set to commence recruitment of 15 patients this quarter.

The patients will be treated with the OncoSil device by percutaneous application, meaning that a needle will be inserted directly through the skin into the pancreatic tumor under CT guidance.

Current approved method of implantation involves the use of endoscopy guided by ultrasound.

The outcome of the study is expected to increase the number of medical professionals who can deliver the OncoSil device to patients. OncoSil says it will provide the doses at no cost for the trial, and will make a modest contribution to study personnel undertaking it.

“Expanding the number of specialties capable of implanting the OncoSil device will assist the company in gaining wider appeal amongst Key Opinion Leaders for the use of the OncoSil treatment, for patients who otherwise would have limited treatment options upon diagnosis of LAPC,” said OncoSil CEO, Nigel Lange.


Korea and Malaysia next stops

Starpharma (ASX:SPL) has achieved regulatory approval for its antiviral nasal spray product, VIRALEZE, in Malaysia.

The registration will allow Starpharma and its commercial partners to sell the product in Malaysia, a country with a population of over 33 million.

VIRALEZE has been well received in other parts of Asia, following successful launches of the product locally in Vietnam, Hong Kong and Macau.

The nasal spray works by physically trapping and blocking cold and respiratory viruses in the nasal cavity.

Multiple nonclinical studies have shown that VIRALEZE traps and blocks a broad spectrum of respiratory viruses, including human coronaviruses, influenza viruses, and rhinoviruses.

Meanwhile, Botanix Pharmaceuticals (ASX:BOT) has secured a new sublicence and distribution agreement for its Sofpironium Bromide product in South Korea.

Dong Wha Pharma, one of Korea’s first and oldest pharmaceutical company, will commercialise Sofpironium Bromide in the Korean market.

Botanix’s partner Kaken and in turn Botanix, will receive a share of upfront payments, milestones and royalties based on net sales of the product.


Share prices today: